Hepatitis C- Global and National Perspective Dr Allister Grant Consultant Hepatologist University Hospitals Leicester NHS Trust.

Slides:



Advertisements
Similar presentations
HEPATITIS C Basic Awareness Viral Hepatitis Team Members: Christine Landon (Lead Nurse) Debbie Jones (Specialist Nurse) Alka Maru (Support Nurse) Tracy.
Advertisements

Hepatitis C in Retrospect David Gladders Portsmouth City Council.
African Americans and Hepatitis C
Integration of Viral Hepatitis Prevention with STD Prevention: What Health Professionals Should Know Presenter: Jay Todd, Training and Public Education.
Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.
Hepatitis B.
Hepatitis B Virus and Cancer Everett Schlam, MD 9/22/2011.
The Global Burden of Hepatitis C Dr Daniel Lavanchy World Health Organization (WHO) Geneva, Switzerland 3 rd Paris Hepatitis Conference.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Liver Disease and Thalassaemia George Constantinou.
Hepatitis C In Alaska’s Department of Corrections
The HIV/AIDS Epidemic © 2005 John B. Pryor Illinois State University.
Hepatitis C Prepared by Division of Viral Hepatitis Centers for Disease Control and Prevention Revised by Jill Gallin, CPNP Assistant Professor of Clinical.
Epidemiology of hepatitis B in Ireland Updated August 2014
Hepatitis C Rapid Antibody Testing Among At-Risk Populations, Arizona, 2014 Felicia McLean Public Health Associate Office for State, Tribal, Local and.
Epidemiology and Control Programs for HBV Infection. Yousef Qari, MD, FRCP(C), ABIM Gastoenterologist King Abdulaziz University Hospital.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
 Primary liver cancer is the fifth most common cancer in the world and the third most common cause of cancer mortality  Hepatocellular carcinomas (HCCs)
Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.
Hepatitis web study H EPATITIS W EB S TUDY Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance.
The HIV/AIDS Epidemic © 2013 John B. Pryor Illinois State University.
MDL UMC utrecht Health Strategy on HCV in The Netherlands van Hattum VHPB meeting May 2002.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
Water Services Trust Fund HIV/ AIDS, STD’s and substance abuse 8/29/20151.
Module 3: HCV prevalence and course of HCV infection.
Hepatitis C Education & Awareness. Women In Government Women In Government Foundation, Inc. is a national, non-profit, non-partisan organization of women.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
Adult Viral Hepatitis Update Roxanne Ereth, MPH, BS Hepatitis C Program Manager Adult Viral Hepatitis Prevention Coordinator.
Surveillance of hepatitis C Infection in France JC Desenclos, Département des Maladies Infectieuses Institut de Veille Sanitaire.
Wyoming Department of Health Communicable Diseases
Harold S. Margolis, M.D. Division of Viral Hepatitis
Hepatitis B Virus 28.
. In the name of God In the name of God. Epidemio logy.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
Prevention and Control of Viral Hepatitis Infection: WHO Framework for Global Action Prevention and Control of Viral Hepatitis Infection: WHO Framework.
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
A TRANSMITTABLE DISEASE AIDS. WHY AIDS? Geographers are concerned with the Geography of AIDS because it has not spread evenly throughout the world and.
Hepatitis C Virus  Genome resembled that of a flavivirus positive stranded RNA genome of around 10,000 bases  1 single reading frame, structural genes.
Overview of Hepatitis B, C, and D Epidemiology in Eastern Europe and the Newly Independent States Michael O. Favorov MD, Ph.D., D.Sc. CDC Central Asia.
What is hepatitis B? Hepatitis B is a virus that infects the liver.
Sara Stevenson Hepatitis B Nurse Specialist St James’s Hospital, Leeds.
Dr Ashley Brown Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, London and Honorary Senior Lecturer, Imperial College London The Updated.
The Swiss Population In 2001 Resident population: 7,258,500 Population density: 176 per Km 2 Foreign nationals: 20.1% (~1,460,000) Excess of births over.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Hepatitis C: The Silent Epidemic Wednesday, October 21, 2015 John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention.
Epidemiologic Update: Hepatitis C
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
How aspirations can be built and levels of performance can be assured: Learning from the Scottish Action Plan Professor Sharon Hutchinson LJWG LDAPF Conference.
Viral Hepatitis Program Management of Babies Born to HBsAg- Positive Mothers Vickie Weeast Perinatal Hepatitis B Case.
Hepatitis C Dr R V S N Sarma., M.D Consultant Physician.
Blood Borne Viruses Refresher Course Occupational Health 2009.
Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
Viral hepatitis overview Itodo Ewaoche 27/02/2015.
Regional Workshop on Viral Hepatitis – WHO SEAR
Hepatitis A, B, C: Overview, Serologies, and Vaccination Connie Tien June 6, 2016.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Viral Hepatitis.
Hepatitis C.
Hepatitis C: Overview and Epidemiology
Hepatitis C Incidence and Prevalence in the U.S.
Hepatitis B and C management pathways in prison:
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
Hepatitis B Hepatitis B is a pathogen, which causes liver disease and inflammation of the liver.
HCV Screening.
Blood borne viral hepatitis action in Wales
Hepatitis C case-finding – An opportunity for community pharmacy
Managing Hepatitis C in Vermont
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

Hepatitis C- Global and National Perspective Dr Allister Grant Consultant Hepatologist University Hospitals Leicester NHS Trust

HCV- Natural History 100 Infected 20% at 20yrs 50% at 30yrs Age Gender Alcohol 20 Clear the HCV 80 Develop Chronic Hepatitis 20 No Harmful Effects 60 Signs/symptoms CIRRHOSIS Transplantation Liver Failure Liver Cancer 3.9% pa 1.4% pa

HCV : Clinical Hepatocellular Carcinoma (Hepatoma) Normal liver Cirrhosis

HCV : Clinical Ascites Oesophageal Varices

Prevalence of Hepatitis C virus 2001 WHO

WHO RegionTotal Population (Millions) Hepatitis C prevalence Rate % Infected Population (Millions) Africa Americas Eastern Mediterranean Europe South-East Asia Western Pacific Total Prevalence of Hepatitis C Virus

WHO Global Burden of Disease 2000 Cirrhosis (all causes) 785,000 deaths per annum from liver failure (cirrhosis, all causes)785,000 deaths per annum from liver failure (cirrhosis, all causes) HBV 40% HBV 40% HCV 25% HCV 25% Other causes 35% Other causes 35% 600,000 deaths per annum from HCC600,000 deaths per annum from HCC HBV 57% HBV 57% HCV18% HCV18% Other causes 25% Other causes 25%

WHO Global Burden of Disease 2000 Mortality from HBV & HCV 1 million deaths per annum1 million deaths per annum Including deaths from cirrhosis and/or liver cancer Including deaths from cirrhosis and/or liver cancer HBV causes 644,000 deaths per annumHBV causes 644,000 deaths per annum HCV causes 325,000 deaths per annumHCV causes 325,000 deaths per annum

WHO Global Burden of Hepatitis Contaminated Healthcare Injections Population receives 3.4 injections per yearPopulation receives 3.4 injections per year 39.3% with used equipment39.3% with used equipment Worst places are SE Asia and Middle East Worst places are SE Asia and Middle East In 2000, unsafe injections causedIn 2000, unsafe injections caused 21 million HBV infections (32% of new infections) 21 million HBV infections (32% of new infections) 2 million HCV infections (40% of new infections) 2 million HCV infections (40% of new infections) Will cause 73,000 early deathsWill cause 73,000 early deaths

Injecting drug use Transfusion or transplant from infected donor Hemodialysis (yrs on treatment) Accidental injuries with needles/sharps Sexual/household exposure to anti-HCV-positive contact Multiple sex partners Birth to HCV-infected mother Risk Factors Associated with Transmission of HCV

UK HCV Prevalence <1% IV Drug Use Migration Blood Donation 200,000

Laboratory reports of infection Injecting Drug users (92%) Blood product Recipients (1%) Blood transfusion (1.4%) Sexual (1.5%) Renal Failure (<1%) Vertical (<1%) Other (2.4%) Risk factors (where reported) PHLS

Injecting Drug Use and HCV Transmission Highly efficientHighly efficient Contamination of drug paraphernalia, not just needles and syringes Rapidly acquired after initiationRapidly acquired after initiation 30% prevalence after 3 years >50% after 5 years Four times more common than HIVFour times more common than HIV

Prevalence of Hepatitis C Antibody (%) Length of Injecting career (years) PHLS Prevalence of antibody to hepatitis C amongst injecting drug users by length of injecting career % HCV

Prevalence of HCV among injecting drug users (Europe)

HCV: Burden of Disease Perspectives for the next 15 years 65% increase in cirrhosis 68% increase in hepatocellular carcinoma 279% increase in decompensated liver disease 528% increase in need for liver transplantation % increase in mortality from HCC Davis et al NEJM 1998 Alter et al NEJM 1999 Deufic et al Hepatology 1999

HCV: Burden of Disease % of the newly diagnosed chronic liver disease 30% of cirrhosis 60% of HCC 30% of the indications for liver transplantation Charlton et al Hepatology 1999 Terrault et al AASLD 2000 EASL Consensus 1999

UK Transplantation for HCV Total HCV recipients

UK Transplantation for HCV Total HCV recipients Total HBV

Birmingham Transplants for HCV UK-born versus OS-born Number of transplants 76/145 (52%) UK born ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ‘01 Year

total donors HCV first graft Supply & Demand

total donors HCV first graft HCV regraft Supply & Demand

total donors HCV first graft HCV regraft total HCV Supply & Demand

HCV Strategy for England 2002 Aims Aims To prevent new cases of Hepatitis C Identify those already infected Offer access to trained specialists & Access to treatment via coordinated pathways

Targeting injecting drug users- Improving needle exchange Harm minimisation info Education- before injecting starts Improving treatment for drug dependency Targeting of prisons and young offenders institutions HCV Strategy for England 2002

Education in schools HCV Awareness campaign Education for primary care health professionals Good practice guidelines (piercing/ tattooing) Increasing HCV testing and treatment HCV Strategy for England 2002

National Plan for Liver Services AIM- Establish commissioning of Hepatology services across the UK for the four components of liver services - Viral Hepatitis - Complications of Cirrhosis - Liver tumours - HPB surgery Provide a framework for the delivery of the hepatitis C Action Plan

“Government to demonstrate greater urgency” “A proactive screening programme is needed especially amongst at risk groups” “…lack of funds should never be an excuse to deny or delay treatment for Hepatitis C.” “Hepatology should be given a higher priority in the NHS” “The awareness campaign directed at the general public and target groups is far too low-key” “All prisoners should be screened on entry to and exit from prison”

How do we compare with other countries? Population HCV Treated 2003 USA273 million Germany82 million France59 million Spain39 million UK60 million2700

Source: CDC Sentinel Counties Study of Acute Viral Hepatitis Surrogate testing of blood donors Anti-HCV test (1st generation) licensed Anti-HCV test (2nd generation) licensed Decline among injecting drug users Decline among transfusion recipients Estimated Incidence of Acute Hepatitis C United States, Cases per 100,000 Year

Time after exposure Hepatitis C Virus Infection Typical Serologic Course Symptoms anti- HCV ALT Normal Titre Titre MonthsYears